


Monoclonal Antibodies for Outpatient Management of COVID-19 Standard Order

Use with COVID-19 Antibody Treatment Referral Form

Addressograph/Place Label Here

These orders are to be used as a guideline and do not replace sound clinical judgement and professional practice standards. Patient allergy and contraindications must be considered when completing these orders. Automatically activated (If not in agreement with an order cross out and initial). Requires a check($$) for activation							
Drug Allergies: Unknown No	☐ Yes (describe)	Wei	ight: k	g Estimated Actual			
MEDICATION OI			GENERAL ORDERS				
For adults 18 years of age or older	r meeting criteria:	Prior to adm					
Drug availability will be based on direction by COVID Incident Cor		■ Confirm that the COVID-19 Monoclonal Antibody Treatment Referral form has been completed					
☐ casirivimab 600 mg and imdevim		■ Prescriber must ensure the criteria for COVID-19 Monoclonal Antibody Treatment Referral has been met					
OR □ sotrovimab 500 mg IV x 1 dose (community sites)	anaphylaxis throughout	Monitoring: ■ Observe and monitor for signs and symptoms of anaphylaxis or other hypersensitivity reaction throughout infusion and for at least 1 hour following completion of infusion					
In case of anaphylaxis: ■ Stop infusion and initiate Anaphy Treatment CLI.5110.SG.009	⁷ laxis Diagnosis and		■ In the case of infusion-related reaction, slow or stop infusion and contact prescriber				
PRESCRIBER'S SIGNATURE:	PRINTED NAM	ME:	Date	Time			
Order Transcribed		FAX TO PHAR	FAX TO PHARMACY				
Date: Time:	Init:	Date:	Time:	Init:			
Medication	n Administration Reco	ord (Pharmacy/	Nurse Use On	dy)			
Medication	Lot Number	Date Administered	Time	Signature			
casirivimab 600 mg and imdevimab 600 mg IV							
sotrovimab 500 mg IV							
Ensure that completed form is faxed or shared for entry into PHIMS within 24 hours:							

COVID-19 Monoclonal Antibody (MAB) Administration Algorithm: Adults 18 years and greater



- a. A patient is considered to have mild or moderate symptoms if they do not require supplemental oxygen (above their baseline), intravenous fluids or physiologic support.
- b. Immunocompromised/suppressed defined as:
 - Active treatment for solid tumor and hematologic malignancies
 - Receipt of solid-organ transplant and taking immunosuppressive therapy
 - Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
 - Moderate or severe primary immunodeficiency (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome)
 - Advanced or untreated HIV infection
 - Active treatment with: high-dose corticosteroids (i.e. equal or greater than 20 mg prednisone or
 equivalent per day when administered for equal or greater than 2 weeks), alkylating agents,
 antimetabolites, transplant-related immunosuppressive drugs, and cancer chemotherapeutic
 agents classified as severely immunosuppressive
 - Tumor-necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory
- c. The following list of underlying medical conditions has been identified by the CDD as associated with a higher risk of severe COVID-19 (including hospital and ICU admission). These co-morbidities are supported by at least one met-analysis or systemic review:
 - Cancer, active treatment of or in follow-up
 - Cerebrovascular disease (stroke, TIAs)
 - Chronic kidney disease or Dialysis patient
 - Chronic lung diseases limited to:
 - o Interstitial lung disease
 - o Pulmonary embolism
 - o Pulmonary hypertension
 - o Bronchopulmonary dysplasia
 - o Bronchiectasis
 - o COPD (chronic obstructive pulmonary disease)
 - chronic liver diseases limited to:
 - o cirrhosis
 - o non-alcoholic fatty liver disease
 - o alcoholic liver disease
 - o autoimmune hepatitis
 - Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)
 - Mental health disorders limited to:
 - Mood disorders, including depression
 - Schizophrenia spectrum disorders
 - Pregnancy and recent pregnancy (in consultation with attending obstetrician)
 - On treatment for tuberculosis

COVID-19 Monoclonal Antibody Treatment Referral
Criteria for Use (Patient must meet mandatory requirements AND one of four criteria)

	Criticia for Ose (1 attent must meet mandatory requirements AND one of four criticia)
Mandat	tory Requirements (all 4 must be met):
	18 years of age or older
	Positive COVID-19 test: Date test performed (D/M/Y)
	Symptom onset within last 7 days: Date of symptom onset (D/M/Y)
	Mild to moderate symptoms (Do not require supplemental oxygen (above their baseline), intravenous fluids, or
	physiologic support; hospital admission or referral to emergency department for COVID-19 evaluation for hospital
	admission NOT imminently required)
If all 4 a	above mandatory requirements are met, proceed to Section One. If not, the individual is not eligible.
Section	One Criteria
	Unvaccinated (zero doses) or partially vaccinated (1 dose of a two dose series)
	No history of a laboratory confirmed COVID-19 infection (1 st positive test)
	>40 years or older
	Section One Criteria met, referral is complete, sign and fax as per below. Otherwise, proceed to Section Two.
	Two Criteria (all 3 criteria plus one risk factor required)
	Unvaccinated (zero doses) or partially vaccinated (1 dose of a two dose series)
	No history of a laboratory confirmed COVID-19 infection (1st positive test)
	18-40 years old
	ave one of the following risk factors (please check all that apply):
	Diabetes (diet controlled, insulin, non-insulin)
	Smoking (current or previous)
	BMI >30: Height (inches/cm), Weight (lbs, kg), BMI
If Section	on Two Criteria met, referral is complete, sign and fax as per below. Otherwise, proceed to Section Three.
Section	nt may complete the form but must indicate the name of the supervising physician. Three Criteria (all 3 criteria plus one risk factor required) Unvaccinated (zero doses) or partially vaccinated (1 dose of a two dose series) No history of a laboratory confirmed COVID-19 infection (1st positive test)
	18-40 years old
AND ha	ave one or more of the following conditions (please check all that apply):
	Cancer, active treatment of, or in follow up, specify type of cancer
	Cerebrovascular disease (stroke, TIA's)
	Chronic kidney disease (estimated GFR<60), or dialysis patient
	Chronic lung diseases limited to:
	Interstitial lung disease
	 Pulmonary embolism
	 Pulmonary hypertension
	o Bronchopulmonary dysplasia
	o Bronchiectasis
	COPD (chronic obstructive pulmonary disease)
	Chronic liver diseases limited to:
	 Cirrhosis Non-alcoholic fatty liver disease
	 Non-alcoholic fatty liver disease Alcoholic liver disease
	Attoinmune hepatitis
	Heart conditions (heart failure, coronary artery disease, or cardiomyopathies)
	Please specify for patients with CHF if they are NYHA Class 3 or Class 4- (Class
	Mental health disorders limited to:
	Mood disorders, including depression
	 Schizophrenia spectrum disorders
	Pregnancy and recent pregnancy
_	Has an obstetrician recommended patient receive treatment? Yes No
	On Treatment for Tuberculosis
If Section	on Three Criteria met, referral is complete, sign and fax as per below. Otherwise, proceed to Section Four.
	1 / 0 1

Section	Four Criteria			
	18 years or older			
AND ha	ive one or more of the following condi	tions (please check all that apply):		
	Active treatment for solid tumor and he		osis	
	Receipt of solid-organ transplant and to			
	Receipt of chimeric antigen receptor (C transplantation or taking immunosuppr		transplant (within 2	years of
	Moderate or severe primary immunode Advanced or untreated HIV infection,		skott-Aldrich syndr	ome),
	Active treatment with high-dose cortic	osteroids (i.e. >20 mg prednisone or ed	uivalent ner dav wh	nen administered
_	for ≥ 2 weeks), alkylating agents, antimotherapeutic agents classified as	netabolites, transplant-related immunosu	appressive drugs, ca	ncer
	Tumor-necrosis factor (TNF) blockers.		unosunnressive or	
	immunomodulatory.	, and other biologic agents that are mini	unosuppressive of	
	illimunomodulatory.			
PRESCR	IBER'S SIGNATURE:	PRINTED NAME:	Date	Time